Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Cidara Therapeutics: A Potential Blockbuster In Flu Prevention
12:52pm, Tuesday, 21'st Oct 2025
Cidara's CD388 is a novel flu prophylactic designed for universal prevention of seasonal and pandemic influenza through a single dose, with potential to be the new standard-of-care. Phase 2 data showe
Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025
08:00am, Tuesday, 21'st Oct 2025
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therape
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
08:00am, Monday, 13'th Oct 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therap
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
01:25pm, Friday, 10'th Oct 2025
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
08:00am, Friday, 10'th Oct 2025
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeuti
Why Cidara Therapeutics Stock Crushed It Today
06:32pm, Thursday, 09'th Oct 2025
The leading pipeline drug being developed by Cidara Therapeutics (CDTX 12.53%) got a real boost from a regulator on Thursday, and the biotech's share price moved accordingly. Cidara's stock closed the
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
08:00am, Thursday, 09'th Oct 2025
Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeut
Why Cidara Therapeutics Was Such a Healthy Stock Today
05:09pm, Friday, 26'th Sep 2025
Cidara Therapeutics (CDTX 6.77%) had some encouraging news to deliver at the end of the trading week, and investors traded the biotech's stock up as a result. It closed Friday nearly 7% higher in pric
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
11:06am, Friday, 26'th Sep 2025
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbiditi
Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High
10:50am, Wednesday, 24'th Sep 2025
Shares of Cidara Therapeutics surged to a five-year high Wednesday on plans to expand testing for its non-vaccine flu prevention drug.
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
07:00am, Wednesday, 24'th Sep 2025
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if su
Cidara Therapeutics (CDTX) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 22'nd Sep 2025
Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation - Preclinical data demonstrating potential eff
